Editor’s Note: As Chief Investment Strategist of Total Wealth, Shah believes in making his track record of recommendations easily accessible to all readers within seconds – and that’s why he’s compiled an Archives page.
“Roads? Where we’re going, we don’t need … roads.”
- Emmett “Doc” Brown, “Back to the Future.”
At the very end of the first “Back to the Future,” Doc Brown (actor Christopher Lloyd) brings his time-machine DeLorean back from “tomorrow,” and tells of a future where roads are obsolete – which is why his car is now able to fly.
Although the first installment of that trilogy hit the big screen way back in 1985, the “future” of the “Back to the Future” franchise predicted where cars can fly and roads are obsolete still hasn’t arrived.
We don’t have flying cars – but the electric vehicle (EV) revolution is in the offing.
And roads remain essential – a disconcerting reality given that the highway system here in America is crumbling, and has been pretty much since the first “Back to the Future” was playing in U.S. movie houses.
Fortunately, our “reality” is about to get better – thanks to the Biden Administration’s $2.25 trillion infrastructure plan. The White House wants to invest $174 billion to help build a nationwide network of 500,000 EV charging stations by 2030. And it’s outlined a $115 billion ante to bring America’s highways and bridges up to snuff.
As we promised in yesterday’s Total Wealth, the urgently needed highway fix-it plan is handing us a moneymaking opportunity we want to jump on right now.
May 19, 2021
An old adage tells us that “Cs get degrees.”
But middling marks like that will never put you on the honor roll.
And that’s America’s problem right now – as well as its challenge.
May 18, 2021
Plug Power Inc. (NasdaqCM:PLUG) reports earnings this Thursday, May 20, 2021, after the bell. If the company disappoints on their numbers the stock could tumble.
In this week’s BS.H, I’m tackling three noxious stocks – stocks considered Wall Street darlings just because they were in the right place at the right time – that have many investors hook, line, and sinker.
But don’t be fooled, no matter how clean they look on the outside, these stocks are as toxic as they come. If you own one of these, you need to think about selling immediately and don’t look back.
Click the video below to find out just which stocks could be holding you back.
May 13, 2021
Click here to download the PDF version The way capital markets operate has changed and continues to change, and it’s further altering how we trade and invest. Amidst all those changes, the one constant thing is what subscribers ask me: …
May 13, 2021
Click here to download the PDF version Sometimes the stocks that hold the biggest opportunities aren’t the ones that are plastered all over the news. Sure, big-name stocks like Microsoft Corp. (NasdaqGS:MSFT) or The Walt Disney Co. (NYSE:DIS) are good …
May 13, 2021
Dear Reader, Click here to download the PDF version There are thousands of ways to make money in the stock market, and to a newcomer, they can be overwhelming. A quick Google search will yield you millions of hits on …
May 13, 2021
Click here to download the PDF version The markets took a massive hit at the start of the coronavirus pandemic last year. But amazingly, people began buying at record volumes. Millennials, boomers, and everyone in between started snapping up stocks …
The number of stocks in the psychedelics space, no pun intended, is expanding like all good universes.
There are already more than 50 publicly traded companies pursuing the billions in new market opportunities in the hallucinogen-based treatment market – a “New Biotech” opportunity I like to refer to as the ‘Shroom Boom.
A lot of these companies are innovative cousins to conventional biotech firms. Like their better-known counterparts, these upstarts are pursuing new drugs, compounds, therapies, and treatment protocols, to arrest or even cure mental illnesses, substance abuse, pain, PTSD, and even chronic brain disorders. The big difference: These ‘Shroom Boom ventures are incorporating psychedelics in their research and trials.
I’ve also identified “pick-and-shovel” companies whose path to sales-and-profits relies on sourcing and manufacturing psychedelics or building infrastructure, like clinics and training therapists.
Here are four companies I like. Two cover the research, trials, and biotech potential of psychedelics. The other two are pick-and-shovels plays that have ID’d innovative ways to apply their trade on this new trend.
I came of age in the late ’60s and early ’70s, which means I’m no stranger to recreational drugs, from pot to psychedelics. Like, I’ve seen things, man – and could tell you some stories. And I was so fascinated by what I saw that I got with the program, and dug deep into the story behind the story.
LSD was still legal. Research was going full bore. And I understood these drugs had promise – real promise.
That all ended in October 1968, when the U.S. made it illegal to possess the hallucinogen. And thanks to that, the research slowly died.
But psychedelics are making a comeback. And I’m groovin’ on all the hip research and FDA trials, and the crazy number of publicly traded companies chasing riches in the psychedelics rainbow.
Can you dig it? You should. There’s evidence psychedelics have the potential to arrest – and maybe even cure – a host of disorders from depression to brain trauma. And if these drugs work – and if you’re into the right stocks – you could end up on the trip of your life, and watch as your portfolio gets high … and I mean really high, man.
If you’re watching the markets and looking at this “new biotech,” you’re no doubt hearing about the tremendous promise of the marijuana legalization, the cannabis market – and the pot-stock boom.
Maybe you missed the pot-stock run the first time around. Or maybe you can’t bring yourself to invest in something in something that’s been maligned so much for so many years.
Don’t sweat it – because here’s the heavy truth: The real opportunity is with psychedelics.
Call it the Shroom Boom.
And I’m going to lay it on you here…
May 11, 2021
Last Tuesday, I mentioned I liked buying the MRNA June 18, 2021 $165/170 Put Spread to take advantage of what looked like an opportunity for a quick reversal in Moderna, Inc. (NasdaqGS:MRNA).
By Thursday, just two days later, shares of MRNA had dropped as much as 23%, and the MRNA June 18, 2021 $165/170 Put Spread had gained more than 400%
The Latest from the Watchlist – Vaccine Stock Flops, Chinese Market Giants, and the Movie Theater Revival
Now I don’t mean to say, “I told you so,” but Varney & Co. didn’t call me the “Man Who Calls It All” for nothing. Just as I predicted a few months back, Pfizer (PFE) stands to lose its COVID-19 vaccine patents and their company’s profitability is about to tank. Hard.
That’s leaves us a wide opening to make some serious profits with its downfall, but that’s not all on my watchlist today.
Early this morning, you should have gotten my watchlist update. Those will be coming in hot every Monday before the opening bell, so make sure to keep your eyes peeled!
If you missed it, don’t worry. You can read all about my favorite stocks for the week here.
Or, just click the video below because I am back with yet another video to take an even deeper dive into these stocks. PFE may be on its way out, but two other heavy-hitting Chinese stocks, NIO and BABA, are going to take off before the year is out.
Tech stocks own the market, but that doesn’t mean you should go blindly into them. That’s what most people will do – but you shouldn’t.
Putting the hype before the horse means you’ll almost always wind up with losers disguised as the next Amazon. So, in today’s BS.H, you’ll hear about three tech stocks that run the gauntlet from the good, the bad, and the exceptionally ugly. I go over their profits, their debts, and whether they’re fit to buy, sell, or hold.
With COVID-19 vaccination programs rolling along, it might well be assumed that any stock tied to vaccinations is on a one-way trip higher.
With legalization around the corner for so many states in the U.S., several of you were asking: “To buy or not to buy?”
That is the question… A few years back I would have given a resounding heck no. But I have to say, I’m starting to change my mind about two of the biggest pot stocks on the market right now.